

Supplementary Table 5. Baseline characteristics of patients (effectiveness analysis set)

Variable	Effectiveness analysis set (n=2,567)
Age, yr	56.25±11.34
<65	1,954 (76.12)
≥65	613 (23.88)
<75	2,459 (95.79)
≥75	108 (4.21)
Male sex	1,473 (57.38)
BMI, kg/m ²	27.33±3.99
<25	631 (29.68)
≥25	1,495 (70.32)
Height, cm	164.84±9.04
Weight, cm	74.38±13.93
Duration of diabetes, yr	7.30±7.10
<4	1,110 (43.24)
≥4 to <8	481 (18.74)
≥8	976 (38.02)
Smoking status	
Never smoked	1,690 (65.84)
Ex-smoker	435 (16.95)
Currently smokes	442 (17.22)
HbA1c, %	7.98±1.38
FPG, mg/dL	163.89±54.70
SBP, mm Hg	129.76±15.09
DBP, mm Hg	77.87±10.58
eGFR, mL/min/1.73 m ²	92.86±20.86
<60	0
≥60 to <90	1,261 (49.88)
≥90 to <120	1,015 (40.15)
≥120	252 (9.97)

(Continued to the next)

Supplementary Table 5. Continued

Variable	Effectiveness analysis set (n=2,567)
Kidney disease	93 (3.62)
Liver disease	344 (13.40)
Diabetic complications	767 (29.88)
Retinopathy	308 (12.00)
Neuropathy	399 (15.54)
Nephropathy	67 (2.61)
Vasculopathy	174 (6.78)
Other disease	2,397 (93.38)
Hypertension	1,590 (61.94)
Dyslipidemia	1,818 (70.82)
Coronary artery disease	829 (32.29)
Stroke	125 (4.87)
Other anti-diabetic drug	2,462 (95.91)
Metformin	2,192 (85.39)
Sulfonylurea	723 (28.17)
DPP4 inhibitor	425 (16.56)
Pioglitazone	92 (3.58)
Insulin	436 (16.98)
Others	642 (25.01)
Dose of study drug, mg	
10	2,287 (89.09)
>10	280 (10.91)

Values are presented as mean ± standard deviation or number (%). BMI, body mass index; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; DPP4, dipeptidyl peptidase 4.